A whitening composition inclusion solution, preparation method and application thereof

Abstract

A whitening composition, comprising a bilayer vesicle-like inclusion body formed with a skin cell membrane structure by phospholipids, polyols, emulsifiers and liquid oils, wherein the phospholipids are the main wall material of the inclusion body, the inclusion body contains an alcohol-soluble main component, an auxiliary component, an antioxidant component and an aqueous solution of a plant extract as an anti-inflammatory component, and a signal molecule is attached to the surface of the inclusion body; in terms of mass percentage, the inclusion body comprises: 1-3% alcohol-soluble main component, 10-50% polyols, 3-15% phospholipids, 1-3% emulsifiers, 1-5% liquid oils, 0.01-0.5% signal molecules, 0.01-2% auxiliary components, 0.01-4% antioxidant components, and 17.5-83.97% aqueous solution of plant extracts. The components of the inclusion solution of the whitening composition can produce a synergistic effect, and have a good whitening effect.

Description

[0001] This application claims priority and benefits of Chinese Patent Application No. 202310337523.4 filed with the State Intellectual Property Office of China on March 31, 2023, the entire contents of which are incorporated herein by reference. Technical Field

[0002] The invention relates to the field of whitening skin care products, and in particular to a whitening composition inclusion solution, a preparation method and application thereof. Background Art

[0003] Glabridin (flavonoids) is a natural plant extract extracted from polyphenols in wild African licorice. Glabridin has multiple effects such as antioxidant, immunomodulatory, anti-inflammatory, and anti-depressant. Studies have shown that glabridin has anti-free radical activity and can effectively inhibit the damage of free radicals to cells.

[0004] The targets of glabridin and some other common whitening agents are located in the nucleus of melanocytes. When the α-MSH signaling molecule binds to the MC1-R receptor on the melanocyte membrane, it causes intracellular reactions such as upregulation of protein kinase A expression, and the activated tyrosinase catalyzes tyrosine to eventually form melanin. When inflammation such as allergies, acne or sunburn occurs, it will also induce the binding of α-MSH and MC1-R receptors, upregulating the expression of inflammatory factors such as IL-1, IL-6, IL-8 and TNF-α, and ultimately leading to pigmentation after the inflammation heals. Therefore, the formation of melanin is caused by a series of complex reactions in melanocytes. To achieve a good whitening effect, in addition to inhibiting tyrosinase activity, it is also necessary to consider it from different angles.

[0005] Existing technical solutions: ① CN108451837A also compounded and encapsulated functional ingredients for different whitening mechanisms to achieve multi-target whitening and facilitate formulation application. ② CN114796008A encapsulates glabridin and polypeptides at the same time. ③ CN115778886A discloses a glabridin plant-derived microcapsule inclusion and a preparation method thereof. However, the inventors of the present invention found that the products obtained from the above-mentioned technical solutions of the prior art have problems such as poor stability (for example, the color turns pink or yellow after being placed at room temperature for 30 days) and poor whitening effect.

[0006] Therefore, there is still an urgent need for a whitening product with good stability and good whitening effect. Summary of the invention

[0007] In view of the above problems, the present invention aims to provide a whitening composition inclusion solution with better whitening efficacy, a preparation method and application thereof.

[0008] To achieve the technical purpose, in the first aspect, the present invention provides a method for preparing a nanoscale bilayer inclusion, the specific steps of which are as follows:

[0009] S1. In terms of mass percentage, 1-3% of the alcohol-soluble main component and 10-50% of the polyol are weighed and mixed in a 65° C. water bath and stirred until dissolved to obtain phase A;

[0010] S2. In terms of mass percentage, 3-15% phospholipid, 1-3% co-emulsifier, 1-5% liquid oil, and 0.01-0.5% signal molecule are weighed and mixed in a 70° C. water bath until dissolved to obtain phase B;

[0011] S3, preparing a plant extract aqueous solution, then weighing 0.01-2% of auxiliary components and 0.01-4% of antioxidant components by mass percentage, dissolving them in a 17.5-83.97% plant extract aqueous solution and heating to 65° C. to obtain phase C;

[0012] S4, mixing phase A and phase B and stirring evenly, and then adding phase C for emulsification to obtain a crude emulsion;

[0013] S5. Processing the crude emulsion by high pressure shearing at 30-40° C. to obtain nano-scale inclusions, and finally obtaining a whitening composition inclusion solution.

[0014] Preferably, the output power of the emulsifier used in step S4 is 0.2 kW, the rotation speed is 3000-8000 rpm, and the high-speed shear dispersion time is 3-10 min;

[0015] The shear pressure is 400-1000bar, and the number of cyclic shearing is 5-10 times.

[0016] Preferably, the plant extract aqueous solution is an extract aqueous solution of herbal anti-inflammatory plants, and the herbal anti-inflammatory plants are one or more combinations of peony flowers, peony roots, roses, and purslane.

[0017] Preferably, in step S3, the herbal anti-inflammatory plant is washed, dried and crushed to obtain plant powder, and the plant powder is boiled and refluxed with water at a mass ratio of 1:10-1:20 at 50-80°C for 8-24 hours to obtain a boiling solution, and then the boiling solution is filtered, with a volume ratio of filtrate: macroporous anion exchange resin = 10-15:1, and a retention time of 15-25 minutes, to obtain a purified plant extract aqueous solution.

[0018] Preferably, the alcohol-soluble main component is glabridin, the auxiliary component is glutathione, and the signal molecule is palmitoyl tripeptide-8.

[0019] Preferably, the polyol is one or more combinations of glycerol, propylene glycol, butylene glycol, dipropylene glycol, pentylene glycol, and isoprene glycol;

[0020] The auxiliary emulsifier is one or more combinations of polyglyceryl-10 stearate, polyglyceryl-10 laurate, polyglyceryl-10 oleate, polyoxyethylene hydrogenated castor oil, and potassium cetyl phosphate;

[0021] The liquid oil is one or more combinations of caprylic / capric triglyceride, meadowfoam seed oil, squalane, olive oil, and peony seed oil;

[0022] The phospholipid is one or more combinations of soybean lecithin, hydrogenated lecithin, and soybean phosphatidylcholine;

[0023] The antioxidant component is one or more combinations of vitamin C, 3-o-ethyl ascorbic acid, ascorbyl glucoside, magnesium ascorbyl phosphate, sodium ascorbyl phosphate, and ascorbic acid polypeptide.

[0024] Preferably, the ratio of the whitening composition inclusion solution is, by mass percentage, 1.1±0.1% glabridin, 20±5% polyol, 6±2% phospholipid, 2±0.5% co-emulsifier, 2±0.5% liquid oil, 0.15±0.05% palmitoyl tripeptide-8, 1±0.2% glutathione, 3±0.5% antioxidant ingredient, and 60±15% aqueous solution of plant extract.

[0025] In some embodiments, the particle size of the nanoscale bilayer inclusions prepared by the above preparation method is 20nm-110nm. In some embodiments, the particle size of the nanoscale bilayer inclusions prepared by the above preparation method is 30nm-110nm. In some embodiments, the particle size of the nanoscale bilayer inclusions prepared by the above preparation method is 30nm, 80nm or 110nm.

[0026] In a second aspect, the present invention provides a whitening composition inclusion solution obtained by the preparation method described in the first aspect.

[0027] A highly transparent and stable whitening composition inclusion solution prepared by the preparation method of the nanoscale bilayer inclusion described in the first aspect, wherein the inclusions use phospholipids as the main wall material, and contain alcohol-soluble main components, auxiliary components, antioxidant components and plant extracts containing anti-inflammatory components, and signal molecules are attached to the surface of the inclusions.

[0028] In a third aspect, the present invention provides the use of the aforementioned whitening composition inclusion solution.

[0029] An application of the whitening composition inclusion solution described in the second aspect in the field of cosmetics.

[0030] Alcohol-soluble main component Alcohol-soluble main component Alcohol-soluble main component The beneficial effect of the present invention is that the components of the whitening composition inclusion solution of the present application have good synergy, which can achieve good whitening effect; at the same time, the whitening composition inclusion solution of the present application is an inclusion containing a bimolecular encapsulation structure, which has good stability, can stably encapsulate the active ingredients therein, and is easily absorbed by the skin; traditional palmitoyl tripeptide-8 is only used as a polypeptide with soothing and anti-allergic effects (and palmitoyl tripeptide-8 also has an α-MSH bionic effect), and the present application uses palmitoyl tripeptide-8 as a target peptide, and palmitoyl tripeptide-8 has a biphilic property and is effectively attached to the surface of the inclusion to form a target point, wherein the hydrophilic group of palmitoyl tripeptide-8 can bind to the MC1-R receptor of melanocytes; at the same time, glycyrrhizin and glutathione are compounded to produce good synergy, effectively reduce the generation of true melanin, and can further enhance the whitening effect. The proportion of each component in the whitening composition inclusion solution of the present application is strictly selected, which has a relatively obvious effect on the performance of the whitening effect.

[0031] In a fourth aspect, the present invention provides a whitening composition inclusion solution.

[0032] A whitening composition inclusion solution, the preparation method of which comprises:

[0033] (1) mixing 1% glabridin and 20% butanediol in a water bath at 65° C. and stirring until dissolved to obtain phase A;

[0034] (2) Mix 2% polyglycerol-10 laurate, 1.5% peony seed oil, 5% soybean lecithin, and 0.15% palmitoyl tripeptide-8 in a 70° C. water bath and stir until dissolved to obtain phase B;

[0035] (3) dissolving 1% glutathione and 3% 3-o-ethyl ascorbic acid in a 66.35% rose water solution and heating the mixture to 65° C. to obtain phase C;

[0036] The preparation of the rose water solution comprises: washing, drying and crushing a herbal anti-inflammatory plant to obtain plant powder, wherein the herbal anti-inflammatory plant is a rose, boiling and refluxing the plant powder with water at a mass ratio of 1:15 at 60° C. for 8 hours to obtain a boiling solution, and then filtering the boiling solution, wherein the volume ratio of the filtrate: macroporous anion exchange resin is 10:1, and the retention time is 20 minutes, thereby obtaining a purified plant extract water solution;

[0037] (4) mixing phase A and phase B while stirring, and then adding phase C to emulsify to obtain a crude inclusion emulsion;

[0038] (5) The crude emulsion is treated to nanoscale by high-pressure shearing, and the circulating water bath is controlled at 30-40° C. and 800 bar pressure for 6 times to obtain a whitening composition inclusion solution.

[0039] In some embodiments, the zeta potential of the whitening composition inclusion solution is -34 mV.

[0040] In some embodiments, the particle size of the inclusions in the whitening composition inclusion solution is 30 nm. DETAILED DESCRIPTION

[0041] The present invention is further described in detail below with reference to specific embodiments.

[0042] The specific embodiment of the present invention is a preparation method for preparing a whitening composition inclusion solution, and the specific steps are as follows:

[0043] S101, mixing glabridin and polyol according to proportion in a 65° C. water bath and stirring until dissolved to obtain phase A;

[0044] S102, mixing the co-emulsifier, liquid oil, phospholipid, and palmitoyl tripeptide-8 in a 70° C. water bath in proportion and stirring until dissolved to obtain phase B;

[0045] S103, prepare a plant extract aqueous solution, wash, dry and crush the herbal anti-inflammatory plant to obtain plant powder, boil and reflux the plant powder and water at a mass ratio of 1:10-1:20 at 50-80°C for 8-24 hours to obtain a boiling solution, and then filter the boiling solution, the volume ratio of filtrate: macroporous anion exchange resin = 10-15:1, the retention time is 15-25 minutes, and the purified plant extract aqueous solution is obtained. The plant extract aqueous solution is an extract aqueous solution of herbal anti-inflammatory plants, and the herbal anti-inflammatory plants are one or more combinations of peony flowers, peony roots, roses, and purslane.

[0046] S104, then dissolving glutathione and antioxidant components in the plant extract aqueous solution according to proportion and heating to 65° C. to obtain phase C;

[0047] S105, firstly mix phase A and phase B in proportion and stir evenly, and then add phase C for emulsification to obtain a crude emulsion;

[0048] S106, the crude emulsion is treated to nanometer level by high pressure shearing at 30-40°C, the output power of the emulsifier is 0.2kW, the rotation speed is 3000-8000rpm, the high-speed shearing dispersion time is 3-10min, the shearing pressure is 400-1000bar, and the number of cyclic shearing is 5-10 times. Finally, a whitening composition inclusion solution with high transparency and stability is obtained.

[0049] Application of whitening composition inclusion solution, the whitening composition inclusion solution can be used as a raw material for cosmetics, the mass ratio of the whitening composition inclusion solution in general cosmetics is 0.5-10%, and the whitening composition inclusion solution can be made into cosmetics in the form of emulsion, cream, gel, etc.

[0050] A whitening composition inclusion solution, the whitening composition inclusion solution contains a bilayer vesicle-shaped inclusion with a skin cell membrane structure formed by phospholipids, polyols, emulsifiers and liquid oils, wherein the phospholipids are the main wall material of the inclusion, and the inclusion contains glabridin (alcohol-soluble main component), glutathione (auxiliary component), antioxidant components and anti-inflammatory components in a plant extract aqueous solution, and palmitoyl tripeptide-8 (signal molecule) is attached to the surface of the inclusion;

[0051] Calculated by mass percentage, it includes: 1-3% glabridin, 10-50% polyol, 3-15% phospholipid, 1-3% co-emulsifier, 1-5% liquid oil, 0.01-0.5% palmitoyl tripeptide-8, 0.01-2% glutathione, 0.01-4% antioxidant component, and 17.5-83.97% aqueous solution of plant extract.

[0052] The polyol is one or more combinations of glycerol, propylene glycol, butylene glycol, dipropylene glycol, pentylene glycol, and isopentyl glycol; the co-emulsifier is one or more combinations of polyglyceryl-10 stearate, polyglyceryl-10 laurate, polyglyceryl-10 oleate, polyoxyethylene hydrogenated castor oil, potassium cetyl phosphate, and potassium phosphate; the liquid oil is one or more combinations of caprylic / capric triglyceride, white meadowfoam seed oil, squalane, olive oil, and peony seed oil; the phospholipid is one or more combinations of soybean lecithin, hydrogenated lecithin, and soybean phosphatidylcholine; the antioxidant ingredient is one or more combinations of vitamin C, 3-o-ethyl ascorbic acid, ascorbyl glucoside, magnesium ascorbyl phosphate, sodium ascorbyl phosphate, and ascorbic acid polypeptide.

[0053] Glabridin has a resorcinol structure and has potential value in whitening effects, but it is difficult to use in formulations because it is difficult to dissolve in water and oil. At the same time, glabridin is easily oxidized and discolored when exposed to light, so technology is needed to improve its stability.

[0054] The technical principle of the present application is: the inclusion body adopts palmitoyl tripeptide-8 as the target peptide, and the hydrophilic group exposed by it inlaid in the inclusion body is used as a signal molecule (the hydrophilic group exposed to the water phase is used as the inclusion body targeting signal molecule to bind to the MC1-R receptor), which can effectively increase the affinity between the inclusion body and melanocytes, thereby increasing the efficacy of the composition.

[0055] At the same time, the whitening effect of glabridin is further enhanced by compounding it with glutathione: the main whitening mechanism of glabridin is to inhibit the activity of tyrosinase, thereby inhibiting the reaction of melanin production; Glutathione: Melanin is divided into eumelanin (black to dark brown pigment) and pheomelanin (reddish brown to yellow) and other uncommon types. The melanin in the human epidermis is mainly mostly eumelanin and a small part of pheomelanin. Dopaquinone formed by tyrosine catalyzed by tyrosinase is partially synthesized into pheomelanin in the presence of glutathione, and most of the rest is synthesized into eumelanin. Artificially increasing the concentration of glutathione can promote more dopaquinone to form lighter pheomelanin, thereby reducing the production of darker eumelanin; Vitamin C or vitamin C derivatives: Anti-oxidation, reducing the formed melanin to a colorless structure; Plant extract aqueous solution: Anti-inflammatory.

[0056] Emulsifiers such as soybean lecithin or hydrogenated lecithin with critical stacking parameters in the range of 1 / 2-1 are selected as the main wall material of the inclusion body to form bilayer vesicles with a skin cell membrane structure, so that water-soluble active substances can be encapsulated in the inner water phase, which also plays a role in promoting penetration.

[0057] Example 1

[0058] (1) Mix 2% glabridin and 50% glycerol in a water bath at 65° C. and stir until dissolved to obtain phase A.

[0059] (2) Mix 3% polyglycerol-10 stearate, 2% meadowfoam seed oil, 10% hydrogenated lecithin, and 0.05% palmitoyl tripeptide-8 in a 70° C. water bath and stir until dissolved to obtain phase B.

[0060] (3) 1% glutathione and 2% ascorbyl glucoside by mass ratio are dissolved in 29.95% peony root aqueous solution (prepared by step S103, the plant extract aqueous solution is prepared, the herbal anti-inflammatory plant is washed, dried and crushed to obtain plant powder, the plant powder and water are boiled and refluxed at 60° C. in a mass ratio of 1:15 for 8 h to obtain a boiling solution, and the boiling solution is filtered, the volume ratio of filtrate: macroporous anion exchange resin = 10:1, the retention time is 20 min, and the purified plant extract aqueous solution is obtained) and heated to 65° C. to obtain phase C.

[0061] (4) After mixing phase A and phase B while stirring, add phase C to emulsify and obtain a crude inclusion emulsion.

[0062] (5) The crude emulsion is treated to nanoscale by high-pressure shearing, and the circulating water bath is controlled at 30-40° C. and 800 bar pressure for 6 times to obtain a whitening composition inclusion solution with a zeta potential of -28 mV, wherein the particle size of the inclusion is 80 nm.

[0063] Example 2

[0064] (1) Mix 3% glabridin and 30% dipropylene glycol in a water bath at 65° C. and stir until dissolved to obtain phase A.

[0065] (2) Mix 3% polyglycerol-10 oleate, 2% caprylic / capric triglyceride, 8% soybean lecithin, and 0.1% palmitoyl tripeptide-8 in a 70° C. water bath and stir until dissolved to obtain phase B.

[0066] (3) Dissolve 1.5% glutathione and 3% ascorbyl glucoside in a 49.4% peony root aqueous solution (prepared in step S103, with the same proportion as in Example 1) and heat to 65° C. to obtain phase C.

[0067] (4) After mixing phase A and phase B while stirring, add phase C to emulsify and obtain a crude inclusion emulsion.

[0068] (5) The crude emulsion is treated to nanoscale by high-pressure shearing, and the circulating water bath is controlled at 30-40° C. and 800 bar pressure for 6 times to obtain a whitening composition inclusion solution with a zeta potential of −22 mV, wherein the particle size of the inclusion is 110 nm.

[0069] Example 3

[0070] (1) Mix 1% glabridin and 20% butanediol in a water bath at 65° C. and stir until dissolved to obtain phase A.

[0071] (2) Mix 2% polyglycerol-10 laurate, 1.5% peony seed oil, 5% soybean lecithin, and 0.15% palmitoyl tripeptide-8 in a 70° C. water bath and stir until dissolved to obtain phase B.

[0072] (3) Dissolve 1% glutathione and 3% 3-o-ethyl ascorbic acid in a 66.35% rose water solution (prepared in step S103, with the same proportion as in Example 1) and heat to 65° C. to obtain phase C.

[0073] (4) After mixing phase A and phase B while stirring, add phase C to emulsify and obtain a crude inclusion emulsion.

[0074] (5) The crude emulsion is treated to nanometer scale by high pressure shearing, and the circulating water bath is controlled at 30-40° C. and 800 bar pressure for 6 times to obtain a whitening composition inclusion solution with a zeta potential of -34 mV, wherein the inclusion particle size is 30 nm. In Example 3, the effective ingredient included is of appropriate amount, and the inclusion particle size is moderate.

[0075] By adopting the preparation methods of Examples 1-3, a stable whitening composition inclusion solution can be obtained. After being placed for 30 days, the whitening composition inclusion solution obtained in Examples 1-3 can maintain a high transparency and slightly blue appearance, uniformity, and no agglomeration. Since Examples 1 and 2 contain a high content of the main active ingredient glabridin, the particle size of the formed annular vesicles increases with the increase of the component content, resulting in the whitening composition inclusion solution obtained in Example 2 having the largest particle size, followed by Example 1, and the smallest in Example 3. Because the smaller the inclusion particle size, the easier it is to be transdermally absorbed through the pathway of the skin cell gap, in order to verify the efficacy of the composition obtained under the optimal conditions of the preparation method, Example 3 is subsequently selected for comparison with the comparative example.

[0076] Comparative Example 1: No Palmitoyl Tripeptide-8 was added

[0077] (1) Mix 1% glabridin and 20% butanediol in a water bath at 65° C. and stir until dissolved to obtain phase A.

[0078] (2) Mix 2% polyglycerol-10 laurate, 1.5% peony seed oil, and 5% soybean lecithin in a 70° C. water bath and stir until dissolved to obtain phase B.

[0079] (3) Dissolve 1% glutathione and 3% 3-o-ethyl ascorbic acid in a 66.5% peony flower aqueous solution (prepared in step S103, with the same proportion as in Example 1) and heat to 65° C. to obtain phase C.

[0080] (4) After mixing phase A and phase B while stirring, add phase C to emulsify and obtain a crude inclusion emulsion.

[0081] (5) The crude emulsion was treated to nanoscale by high pressure shearing, and the circulating water bath was controlled at 30-40° C. and 800 bar pressure for 6 cycles to obtain a whitening composition inclusion solution with a zeta potential of -34 mV, wherein the inclusion particle size was 30 nm. In Comparative Example 1, palmitoyl tripeptide-8 was not added.

[0082] Comparative Example 2: No emulsifier added

[0083] (1) Mix 1% glabridin and 20% butanediol in a water bath at 65° C. and stir until dissolved to obtain phase A.

[0084] (2) Mix 1.5% peony seed oil, 5% soybean lecithin, and 0.15% palmitoyl tripeptide-8 in a 70° C. water bath and stir until dissolved to obtain phase B.

[0085] (3) Dissolve 1% glutathione and 3% 3-o-ethyl ascorbic acid in a 68.5% peony flower aqueous solution (prepared in step S103, with the same proportion as in Example 1) and heat to 65° C. to obtain phase C.

[0086] (4) After mixing phase A and phase B while stirring, add phase C to emulsify and obtain a crude inclusion emulsion.

[0087] (5) The crude emulsion was treated to nanometer scale by high pressure shearing, and the circulating water bath was controlled at 30-40° C. and 800 bar pressure for 6 times to obtain a whitening composition inclusion solution with a zeta potential of -29 mV, wherein the inclusion particle size was 106 nm. In Comparative Example 2, no auxiliary emulsifier was added, and the inclusion particle size would be larger at this time.

[0088] Comparative Example 3: High-pressure shearing treatment temperature is 10-15°C

[0089] (1) Mix 1% glabridin and 20% butanediol in a water bath at 65° C. and stir until dissolved to obtain phase A.

[0090] (2) Mix 2% polyglycerol-10 laurate, 1.5% peony seed oil, 5% soybean lecithin, and 0.15% palmitoyl tripeptide-8 in a 70° C. water bath and stir until dissolved to obtain phase B.

[0091] (3) Dissolve 1% glutathione and 3% 3-o-ethyl ascorbic acid in a 66.5% peony flower aqueous solution (prepared in step S103, with the same proportion as in Example 1) and heat to 65° C. to obtain phase C.

[0092] (4) After mixing phase A and phase B while stirring, add phase C to emulsify and obtain a crude inclusion emulsion.

[0093] (5) The crude emulsion was treated to nanometer scale by high-pressure shearing, and the circulating water bath was controlled at 10-15°C and 800 bar pressure was cyclically sheared 6 times to obtain a whitening composition inclusion solution with a zeta potential of -32mV, wherein the particle size of the inclusion was 103nm. In Comparative Example 3, the high-pressure shearing process was at a relatively low temperature, and the softness of the phospholipid bilayer membrane was reduced, making it difficult for the composition to be homogenized into small-particle inclusions with uniform particle size. When the particle size distribution of the inclusions in the composition is relatively wide, the vesicles with large particle size differences will fuse due to Ostwald ripening, and the Brownian motion caused by the increase of time or the increase of ambient temperature will intensify. Ripening eventually causes most of the vesicles to aggregate and fuse, and stratification occurs from the macroscopic appearance.

[0094] Comparative Example 4: Palmitoyl Tripeptide-8 replaced by Nonapeptide-1

[0095] (1) Mix 1% glabridin and 20% butanediol in a water bath at 65° C. and stir until dissolved to obtain phase A.

[0096] (2) Mix 2% polyglycerol-10 laurate, 1.5% peony seed oil, and 5% soybean lecithin in a 70° C. water bath and stir until dissolved to obtain phase B.

[0097] (3) 1% glutathione, 3% 3-o-ethyl ascorbic acid, and 0.02% nonapeptide-1 were dissolved in 66.48% peony flower aqueous solution (prepared in step S103, with the same proportion as in Example 1) and heated to 65° C. to obtain phase C.

[0098] (4) After mixing phase A and phase B while stirring, add phase C to emulsify and obtain a crude inclusion emulsion.

[0099] (5) The crude emulsion was treated to nanoscale by high-pressure shearing, and the circulating water bath was controlled at 30-40°C and 800 bar pressure for 6 cycles to obtain a whitening composition inclusion solution with a zeta potential of -34 mV, wherein the particle size of the inclusion was 30 nm. In Comparative Example 4, palmitoyl tripeptide-8 was not added, and nonapeptide-1 without amphiphilicity was used as a signal molecule (but nonapeptide-1 has α-MSH antagonism).

[0100] Comparative Example 5: Using Palmitoyl Tetrapeptide-7 to Replace Palmitoyl Tripeptide-8

[0101] (1) Mix 1% glabridin and 20% butanediol in a water bath at 65° C. and stir until dissolved to obtain phase A.

[0102] (2) Mix 2% polyglycerol-10 laurate, 1.5% peony seed oil, 5% soybean lecithin, and 0.06% palmitoyl tetrapeptide-7 in a 70° C. water bath and stir until dissolved to obtain phase B.

[0103] (3) Dissolve 1% glutathione and 3% 3-o-ethyl ascorbic acid in a 66.44% peony flower aqueous solution (prepared in step S103, with the same proportion as in Example 1) and heat to 65° C. to obtain phase C.

[0104] (4) Phase A and phase B are mixed while stirring, and then phase C is added for emulsification to obtain a crude inclusion emulsion.

[0105] (5) The crude emulsion was treated to nanoscale by high-pressure shearing, and the circulating water bath was controlled at 30-40°C and 800 bar pressure for 6 cycles to obtain a whitening composition inclusion solution with a zeta potential of -28mV, wherein the particle size of the inclusion was 38nm. In Comparative Example 5, palmitoyl tripeptide-8 was not added, and amphiphilic palmitoyl tetrapeptide-7 was used as a signal molecule (but palmitoyl tetrapeptide-7 does not have an α-MSH antagonistic effect).

[0106] Comparative Example 6: Using Palmitoyl Pentapeptide-4 to replace Palmitoyl Tripeptide-8

[0107] (1) Mix 1% glabridin and 20% butanediol in a water bath at 65° C. and stir until dissolved to obtain phase A.

[0108] (2) Mix 2% polyglycerol-10 laurate, 1.5% peony seed oil, 0.06% palmitoyl pentapeptide-4, and 5% soybean lecithin in a 70° C. water bath and stir until dissolved to obtain phase B.

[0109] (3) Dissolve 1% glutathione and 3% 3-o-ethyl ascorbic acid in a 66.44% peony flower aqueous solution (prepared in step S103, with the same proportion as in Example 1) and heat to 65° C. to obtain phase C.

[0110] (4) Phase A and phase B are mixed while stirring, and then phase C is added for emulsification to obtain a crude inclusion emulsion.

[0111] (5) The crude emulsion was treated to nanoscale by high-pressure shearing, and the circulating water bath was controlled at 30-40°C and 800 bar pressure for 6 cycles to obtain a whitening composition inclusion solution with a zeta potential of -25mV, wherein the particle size of the inclusion was 34nm. In Comparative Example 6, palmitoyl tripeptide-8 was not added, and amphiphilic palmitoyl pentapeptide-4 was used as a signal molecule (but palmitoyl pentapeptide-4 does not have an α-MSH antagonistic effect).

[0112] Comparative Example 7: No lecithin added

[0113] (1) Mix 1% glabridin and 20% butanediol in a water bath at 65° C. and stir until dissolved to obtain phase A.

[0114] (2) Mix 6% polyglycerol-10 laurate, 1.5% peony seed oil, and 0.15% palmitoyl tripeptide-8 in a 70° C. water bath and stir until dissolved to obtain phase B.

[0115] (3) Dissolve 1% glutathione and 3% 3-o-ethyl ascorbic acid in a 67.35% rose water solution (prepared in step S103, with the same proportion as in Example 1) and heat to 65° C. to obtain phase C.

[0116] (4) Phase A and phase B are mixed while stirring, and then phase C is added for emulsification to obtain a crude inclusion emulsion.

[0117] (5) The crude emulsion was treated to nanoscale by high pressure shearing, and the circulating water bath was controlled at 30-40° C. and 800 bar pressure for 6 cycles to obtain a whitening composition inclusion solution with an inclusion particle size of 28 nm and a zeta potential of -32 mV. In Comparative Example 7, no phospholipid was added, and no ring structure was formed in the whitening composition inclusion solution.

[0118] Comparative Example 8: Reference CN115778886A Example 7

[0119] S1. Heat and mix 6% licorice extract, 5% apple extract, 2% rice bran extract, 8% ethylhexyl cocoate, 3% diglyceryl stearate malate, 2% isopropyl myristate, 4% beheneth-20, 4% sorbitol ether-30, 2% ethoxydiglycol, and 5% 1,2-hexanediol at 75° C. to obtain an oil phase; then add 5% propylene glycol and 5% sorbitol to 49% pure water, and heat and dissolve in a water bath at 75° C. to obtain an aqueous phase;

[0120] S2, adding the water phase to the oil phase at a rate of 9 drops / s, and stirring and mixing at 75°C and 1000 rpm. After the mixing is completed, high-speed shearing treatment is performed at a speed of 15000 rpm for 3 minutes to obtain a micron-sized dispersion;

[0121] S3, subjecting the micron-sized dispersion to high-pressure homogenization treatment at 75° C. and a pressure of 800 bar, and repeating the process for 6 times to obtain the glabridin plant-derived microcapsule inclusions.

[0122] Comparative Example 9: Reference CN114796008A Example 1

[0123] Under argon atmosphere, 0.1 g of glabridin and 4 g of polyglycerol-3-methylglucose distearate were dissolved in 0.5 g of jojoba oil, 0.5 g of white meadowfoam seed oil, and 3 g of dicaprylyl carbonate in the oil phase, and the prescribed amount of pentylene glycol, glycerol, trehalose, sodium oleate and water were weighed to 100 g and dissolved as the water phase. After the two phases were completely dissolved, the oil phase was slowly added to the water phase at 80°C under shear conditions, and then high-pressure homogenization was performed at 600 bar and 60°C for 6 times to obtain a supramolecular composition nano solution.

[0124] Comparative Example 10-Comparative Example 11: Investigation of signal molecules

[0125] The palmitoyl tripeptide-8 in Example 3 was replaced by nonapeptide-1, and other conditions were the same as those in Example 3, as the whitening composition inclusion solution of Comparative Example 10.

[0126] The palmitoyl tripeptide-8 in Example 3 was replaced with undecylenoyl phenylalanine, and other conditions were the same as those in Example 3, as the whitening composition inclusion solution of Comparative Example 11.

[0127] Comparative Example 12: Investigation of auxiliary components

[0128] The glutathione in Example 3 was replaced by cysteine, and other conditions were the same as those in Example 3, as the whitening composition inclusion solution of Comparative Example 12.

[0129] Comparative Example 13: Whitening composition inclusion solution containing 0% palmitoyl tripeptide-8 and 1.15% glabridin

[0130] The palmitoyl tripeptide-8 in Example 3 was removed, and the feeding amount of glabridin in Example 3 was changed to 1.15%. The other conditions were the same as those in Example 3, and the whitening composition inclusion solution of Comparative Example 13 was obtained.

[0131] Comparative Example 14: Whitening composition inclusion solution containing 0% glabridin and 1.15% palmitoyl tripeptide-8

[0132] The glabridin in Example 3 was removed, and the mass percentage of palmitoyl tripeptide-8 in Example 3 was changed to 1.15%. The other conditions were the same as in Example 3, and the whitening composition inclusion solution of Comparative Example 14 was obtained.

[0133] Comparative Example 15: Whitening composition inclusion solution containing 0% glutathione and 2% glabridin

[0134] The glutathione in Example 3 was removed, and the mass percentage of glabridin in Example 3 was changed to 2%. The other conditions were the same as in Example 3, and the whitening composition inclusion solution of Comparative Example 15 was obtained.

[0135] Comparative Example 16: Whitening composition inclusion solution containing 0% glabridin and 2% glutathione

[0136] The glabridin in Example 3 was removed, and the mass percentage of glutathione in Example 3 was changed to 2%. The other conditions were the same as those in Example 3, and the whitening composition inclusion solution of Comparative Example 16 was obtained.

[0137] Test Example 1: Stability Test

[0138] After the above examples or comparative examples were placed at room temperature for 30 days, the particle size, polydispersity coefficient and appearance of the inclusion solution of the whitening composition of each example or comparative example were tested. The results are shown in Table 1.

[0139] Table 1: Stability test results

[0140]

[0141]

[0142] According to Table 1, comparative examples 2 and 3 turned into powder due to the precipitation of glabridin; the glabridin that was normally stably encapsulated did not turn into powder, indicating that the encapsulation in other groups stabilized the glabridin.

[0143] According to Table 1, Comparative Examples 2 and 3 are not included in the comparison because they cannot be stored for a long time and have poor practicality.

[0144] Test Example 2: Whitening Effect Investigation

[0145] Investigation 1: In order to compare the whitening effects between the examples and the comparative examples, the skin analyzers Demalab Combo and VISIA were used to test the samples for efficacy, and the test standard was "Test Method for Whitening and Anti-freckle Efficacy of Cosmetics" T / ZHCA 001-2018. 4% of Example 3, 4% of Comparative Example 1, 4% of Comparative Example 4, 4% of Comparative Example 5, 4% of Comparative Example 6, and 4% of Comparative Example 7 were added to the blank essence, and the MI value and ITA° value of 30 volunteers aged 20 to 60 before and after skin application were tested and compared.

[0146] Investigation 2: Following the same operation, 4% of Example 3, 4% of Comparative Example 8 and 4% of Comparative Example 16 were added to the blank essence, and the MI values ​​and ITA° values ​​before and after skin application were tested and compared on 30 volunteers aged 20 to 60 years old.

[0147] The lower the MI value, the less melanin in the skin, and the whiter the skin looks. The higher the ITA° value, the whiter and brighter the skin.

[0148] Table 2: MI value comparison table

[0149]

[0150] Table 3: ITA° value comparison table

[0151]

[0152]

[0153] Conclusion: As shown in Table 2, the MI values ​​(skin pigment) of Example 3, Comparative Example 1, and Comparative Examples 4 to Comparative Examples 16 showed a significant downward trend with the use time, among which Example 3 had the most significant effect in reducing the skin melanin content (the MI value decreased by 43.7% in the fourth week), which was far superior to Comparative Examples 1 and Comparative Examples 4 to Comparative Examples 16.

[0154] As shown in Table 3, the ITA° values ​​(human skin color) of Example 3, Comparative Example 1, and Comparative Examples 4 to Comparative Examples 16 show a significant upward trend with the use time, among which Example 3 has the most significant effect on improving skin chromaticity (the increase rate of ITA° value in the fourth week reaches 11.0%), which is far superior to Comparative Examples 1 and Comparative Examples 4 to Comparative Examples 16.

[0155] Traditional palmitoyl tripeptide-8 is used as a polypeptide for soothing and anti-allergic effects, rather than as a target peptide. This application uses palmitoyl tripeptide-8 mainly as a target peptide, and takes into account its antagonistic effect. The MI value of Comparative Example 4 decreased second (the MI value decreased by 37.1% in the fourth week, and the ITA° value increased by 7.7%); compared with Example 3, the target peptides of Comparative Examples 4 and Comparative Example 10 were replaced with nonapeptide-1, which also has a very good match with the MC1 receptor on melanocytes. Although it antagonizes α-MSH, it does not have amphiphilicity, resulting in poor targeting carrier effect. The effects of Comparative Examples 1 / 5 / 6 are similar. Although Comparative Examples 5 and 6 use target peptides with structures similar to those of Example 3, palmitoyl tetrapeptide-7 and palmitoyl pentapeptide-4 do not have α-MSH antagonism, resulting in Comparative Examples 5 and Comparative Example 6 having a worse MI value decrease effect than Comparative Example 4. Comparative Example 1 did not use the target peptide, but the MI value reduction effect and ITA° value increase effect were better than those of Comparative Example 5 and Comparative Example 6. In summary, since phospholipid vesicles can encapsulate both water-soluble and oil-soluble active ingredients, combined with the target peptide, the whitening effect can be improved.

[0156] The MI value of Comparative Example 7 decreased the most (the MI value decreased by 35.1% in the fourth week and the ITA° value increased by 8.9%). Compared with Example 3, Comparative Example 7 did not add phospholipids, so no ring structure (bilayer vesicles) was formed. In summary, since phospholipid vesicles can encapsulate active ingredients and cooperate with target peptides, the whitening effect can be improved.

[0157] In addition, from the results of Example 3 and Comparative Examples 8 to 16, it can be seen that when glabridin, palmitoyl tripeptide-8 and glutathione are used at the same time, they have a synergistic effect, and any one of the three components is changed to other similar components. It is difficult to bring about a synergistic technical effect. The synergistic technical effect of the present invention is unexpected.

[0158] In order to further verify the synergistic effect and degree of synergy of each component in the whitening composition inclusion solution of the present application, the applicant conducted an in vitro whitening efficacy comparison between Example 3 and Comparative Examples 17-19 and Test Examples 1-5. The specific operation is as follows:

[0159] Comparative Example 17

[0160] (1) 0.04% glabridin and 5% butanediol (mass ratio) were stirred in a 65° C. water bath until completely dissolved to obtain phase A;

[0161] (2) 0.36% by mass of hydroxypropyl β-cyclodextrin was stirred and dissolved in 94.6% water, and heated to 65° C. to obtain phase B;

[0162] (3) While phase A is being stirred, phase B is slowly added dropwise, and stirring is maintained at 65°C until no particles are visible to the naked eye, to obtain phase C;

[0163] (4) 0.4% by weight of phenoxyethanol as a preservative is added to phase C and stirred until completely dissolved to obtain water-soluble glabridin. This ratio simulates the concentration of 4% of the whitening composition of Example 3 in the water-intake skin care product containing only glabridin.

[0164] Comparative Example 18

[0165] (1) stirring 0.006% palmitoyl tripeptide-8 and 5% butylene glycol at a mass ratio at 65° C. until completely dissolved to obtain phase A;

[0166] (2) adding 0.04% glutathione, 0.12% 3-o-ethyl ascorbic acid, and 2.654% peony flower water (prepared in step S103, with the same proportion as in Example 1) to 91.78% water and stirring at room temperature until completely dissolved to obtain phase B;

[0167] (3) After mixing phase A and phase B, add 0.4% phenoxyethanol and stir until uniform, to obtain a simulated addition of 4% of the whitening composition of Example 3 to the water-intake agent skin care product, containing other active ingredients other than glycyrrhizin and the corresponding concentrations.

[0168] Comparative Example 19

[0169] (1) Mix 0.04% glabridin and 2.5% butanediol in a water bath at 65°C and stir until they are completely dissolved to obtain phase A.

[0170] (2) 0.36% by mass of hydroxypropyl β-cyclodextrin was dissolved in 70% water by stirring, and the mixture was heated to 65° C. to obtain phase B;

[0171] (3) While phase A is being stirred, phase B is slowly added dropwise, and stirring is maintained at 65°C until no particles are visible to the naked eye, to obtain phase C;

[0172] (4) stirring 0.006% palmitoyl tripeptide-8 and 2.5% butanediol at a mass ratio of 65° C. until completely dissolved to obtain phase D;

[0173] (5) adding 0.04% glutathione, 0.12% 3-o-ethyl ascorbic acid, and 2.654% peony flower water (prepared in step S103, with the same proportion as in Example 1) to 21.38% water and stirring at room temperature until completely dissolved to obtain phase E;

[0174] (6) Phase D, phase E and phase C are mixed in sequence, 0.4% phenoxyethanol is added as a preservative, and stirred until uniform, to obtain a simulated addition of 4% of the active ingredients and corresponding concentrations contained in the skin care product of the whitening composition water inlet agent of Example 3.

[0175] Test Example 1: Test sample after dilution in Example 1

[0176] 4% by weight of the inclusion solution of the whitening composition of Example 3 was dissolved in 91.4% water, and 4.2% of butylene glycol and 0.4% of phenoxyethanol were added, and stirred evenly to obtain a test sample of a skin care product simulated by adding 4% of the inclusion solution of the whitening composition of Example 3 into a water-influent agent.

[0177] Test Example 2: Comparative Example 13 diluted test sample

[0178] Dissolve 4% of the whitening composition inclusion solution of Example 13 in 91.4% water, add 4.2% butylene glycol and 0.4% phenoxyethanol, and stir evenly to obtain a test sample of a water-influent skin care product simulating the addition of 4% of the whitening composition inclusion solution of Example 13.

[0179] Test Example 3: Comparative Example 14 diluted test sample

[0180] 4% by mass of the whitening composition inclusion solution of comparative example 14 was dissolved in 91.4% water, and 4.2% butylene glycol and 0.4% phenoxyethanol were added and stirred evenly to obtain a test sample of a water-influent skin care product simulating the addition of 4% of the whitening composition inclusion solution of comparative example 14.

[0181] Test Example 4: Comparative Example 15 diluted test sample

[0182] 4% by mass of the whitening composition inclusion solution of comparative example 15 was dissolved in 91.4% water, and 4.2% butylene glycol and 0.4% phenoxyethanol were added, and stirred evenly to obtain a test sample of a water-influent skin care product simulating the addition of 4% of the whitening composition inclusion solution of comparative example 15.

[0183] Test Example 5: Comparative Example 16 diluted test sample

[0184] 4% by mass of the whitening composition inclusion solution of comparative example 16 was dissolved in 91.4% water, and 4.2% butylene glycol and 0.4% phenoxyethanol were added and stirred evenly to obtain a test sample of a water-influent skin care product simulating the addition of 4% of the whitening composition inclusion solution of comparative example 16.

[0185] Test Example 3: In vitro whitening effect

[0186] Negative control: Based on Example 3, glabridin, palmitoyl tripeptide-8 and glutathione were removed, and the mass ratios of the remaining ingredients were the same as those in Example 3. A blank sample was prepared according to the preparation method of Reference Example 3, and 4% of the blank sample was dissolved in 91.4% water, and 4.2% of butanediol and 0.4% of phenoxyethanol were added, and the mixture was stirred evenly to obtain a negative control.

[0187] 3D melanin skin model To test the synergistic effect of the test tool, the model was irradiated with UVB (50 mJ / cm 2 ), after continuous stimulation for 3 days, the positive control and test examples 1-5 and comparative examples 17-19, and the negative control sample system were administered to the melanin model, and the administration was continued every day. The operation was terminated after continuous stimulation for 6 days. At the same time, a blank control (the L of the model that has not been subjected to UVB irradiation treatment and drug administration operation) was set. * value and melanin content, culture time and other culture conditions were consistent with the test group), and the brightness of the skin model after administration (L * value) and melanin distribution to evaluate the in vitro whitening efficacy of the sample group.

[0188] Table 4: L * Comparison of value and melanin content

[0189]

[0190]

[0191] As shown in Table 4, the L* value and melanin content of Comparative Example 19 are better than those of Comparative Examples 17 and 18, indicating that the compounding of glabridin with palmitoyl tripeptide-8, glutathione, vitamin C or vitamin C derivatives and plant aqueous solution has a synergistic effect. The results of Test Example 1 are all better than those of Comparative Example 19, indicating that the encapsulation using the carrier form of the present invention also has an excellent penetration-enhancing effect.

[0192] The results of Test Example 1 are significantly better than those of Test Example 2-Test Example 5 (the total active ingredients are the same as those of Test Example 1, but Test Example 2-Test Example 5 lack one active ingredient respectively), indicating that glycyrrhizin has an unexpected synergistic effect with palmitoyl tripeptide-8 and glutathione.

[0193] In summary, the present application adopts the compound of glabridin and glutathione, and is supplemented with antioxidant vitamin C or vitamin C derivatives, anti-inflammatory plant extract aqueous solution (reference Example 3 and comparative examples 1 and 7 data), which has played a good synergistic role and can achieve a good whitening effect; at the same time, after strict screening of target peptides, the targeting effect of the active ingredients (glabridin and glutathione, etc.) is improved, thereby further improving the whitening effect, and palmitoyl tripeptide-8 has played a relatively obvious improvement on the inclusion solution of the whitening composition. The compound of glabridin, glutathione and palmitoyl tripeptide-8 has obvious synergistic technical effects.

[0194] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any slight modification, equivalent substitution and improvement made to the above embodiment based on the technical essence of the present invention should be included in the protection scope of the technical solution of the present invention.

Claims

1. A method for preparing a nanoscale bilayer inclusion, characterized in that: The specific steps are as follows: S1. In terms of mass percentage, weigh 1-3% of the alcohol-soluble main component and 10-50% of the polyol, mix and stir in a 65°C water bath until dissolved to obtain phase A; S2. In terms of mass percentage, 3-15% phospholipid, 1-3% co-emulsifier, 1-5% liquid oil, and 0.01-0.5% signal molecule are weighed and mixed in a 70° C. water bath until dissolved to obtain phase B; S3. Prepare a plant extract aqueous solution, then weigh 0.01-2% auxiliary ingredients and 0.01-4% antioxidant ingredients by mass percentage, dissolve them in 17.5-83.97% plant extract aqueous solution and heat to 65°C to obtain phase C; wherein the plant extract aqueous solution is an extract aqueous solution of herbal anti-inflammatory plants, and the herbal anti-inflammatory plants are one or more combinations of peony flowers, peony roots, roses, and purslane; the preparation method of the plant extract aqueous solution comprises: washing, drying, and crushing the herbal anti-inflammatory plants to obtain plant powder, boiling and refluxing the plant powder and water at a mass ratio of 1:10-1:20 at 50-80°C for 8-24h to obtain a boiling solution, and then filtering the boiling solution, the volume ratio of filtrate: macroporous anion exchange resin = 10-15:1, and the retention time is 15-25min, so as to obtain a purified plant extract aqueous solution; S4, mixing phase A and phase B and stirring evenly, and then adding phase C for emulsification to obtain a crude emulsion; S5, subjecting the crude emulsion to high pressure shearing treatment at a temperature of 30-40° C. to obtain nano-scale inclusions, and finally obtaining a whitening composition inclusion solution; Wherein, the alcohol-soluble main component is glabridin, the auxiliary component is glutathione, and the signal molecule is palmitoyl tripeptide-8; The auxiliary emulsifier is one or more combinations of polyglyceryl-10 stearate, polyglyceryl-10 laurate, polyglyceryl-10 oleate, polyoxyethylene hydrogenated castor oil, and potassium cetyl phosphate; The liquid oil is one or more combinations of caprylic / capric triglyceride, meadowfoam seed oil, squalane, olive oil, and peony seed oil.

2. The method for preparing the nanoscale bilayer inclusion according to claim 1, characterized in that: In step S4, the output power of the emulsifier used is 0.2 kW, the rotation speed is 3000-8000 rpm, the high-speed shear dispersion time is 3-10 min; the shear pressure is 400-1000 bar, and the number of cyclic shearing times is 5-10 times.

3. The method for preparing the nanoscale bilayer inclusion according to claim 1, characterized in that: The polyol is one or more combinations of glycerol, propylene glycol, butylene glycol, dipropylene glycol, pentylene glycol, and isoprene glycol; The phospholipid is one or more combinations of soybean lecithin, hydrogenated lecithin, and soybean phosphatidylcholine; The antioxidant component is one or more combinations of vitamin C, 3-o-ethyl ascorbic acid, ascorbyl glucoside, magnesium ascorbyl phosphate, sodium ascorbyl phosphate, and ascorbic acid polypeptide.

4. The method for preparing the nanoscale bilayer inclusion according to any one of claims 1 to 3, characterized in that: In terms of mass percentage, the ratio of the whitening composition inclusion solution is: 1.1±0.1% glabridin, 20±5% polyol, 6±2% phospholipid, 2±0.5% co-emulsifier, 2±0.5% liquid oil, 0.15±0.05% palmitoyl tripeptide-8, 1±0.2% glutathione, 3±0.5% antioxidant ingredient, and 60±15% plant extract aqueous solution. 5 . The method for preparing the nanoscale bilayer inclusion according to claim 1 , wherein the particle size of the nanoscale bilayer inclusion is 20 nm-110 nm or 30 nm-110 nm.

6. A highly transparent and stable whitening composition inclusion solution prepared by the method for preparing nanoscale bilayer inclusions according to any one of claims 1 to 5, wherein: The inclusion body has phospholipid as the main wall material, and contains alcohol-soluble main components, auxiliary components, antioxidant components and plant extracts containing anti-inflammatory components, and signal molecules are attached to the surface of the inclusion body.

7. Use of the whitening composition inclusion solution according to claim 6 in the preparation of cosmetics.

8. A whitening composition inclusion solution, characterized in that: The preparation method thereof comprises: (1) Mix 1% glabridin and 20% butanediol in a water bath at 65°C and stir until dissolved to obtain phase A; (2) Mix 2% polyglycerol-10 laurate, 1.5% peony seed oil, 5% soybean lecithin, and 0.15% palmitoyl tripeptide-8 in a 70°C water bath and stir until dissolved to obtain phase B; (3) dissolving 1% glutathione and 3% 3-o-ethyl ascorbic acid in a 66.35% rose water solution and heating the mixture to 65°C to obtain phase C; The preparation of the rose water solution comprises: washing, drying and crushing a herbal anti-inflammatory plant to obtain plant powder, wherein the herbal anti-inflammatory plant is a rose, boiling and refluxing the plant powder with water at a mass ratio of 1:15 at 60° C. for 8 hours to obtain a boiling solution, and then filtering the boiling solution, wherein the volume ratio of the filtrate: macroporous anion exchange resin is 10:1, and the retention time is 20 minutes, thereby obtaining a purified plant extract water solution; (4) Mixing phase A and phase B while stirring, and then adding phase C to emulsify to obtain a crude inclusion emulsion; (5) The crude emulsion is treated to nanoscale by high-pressure shearing, and the circulating water bath is controlled at 30-40° C. and 800 bar pressure for 6 times to obtain a whitening composition inclusion solution. 9 . The whitening composition inclusion solution according to claim 8 , wherein the zeta potential of the whitening composition inclusion solution is −34 mV. 10 . The whitening composition inclusion solution according to claim 8 , wherein the particle size of the inclusions in the whitening composition inclusion solution is 30 nm.

Images